{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:56:17Z","timestamp":1775163377248,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.juro.2016.03.003","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T03:45:57Z","timestamp":1457495157000},"page":"747-754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis\/Bladder Pain Syndrome"],"prefix":"10.1097","volume":"196","author":[{"given":"J. Curtis","family":"Nickel","sequence":"first","affiliation":[{"name":"Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blair","family":"Egerdie","sequence":"additional","affiliation":[{"name":"University of Western Ontario, London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Davis","sequence":"additional","affiliation":[{"name":"Citrus Valley Medical Centre, Glendora, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Evans","sequence":"additional","affiliation":[{"name":"Wake Forest University, Winston Salem, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lloyd","family":"Mackenzie","sequence":"additional","affiliation":[{"name":"Aquinox Pharmaceuticals (Canada), Inc., Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Shrewsbury","sequence":"additional","affiliation":[{"name":"Aquinox Pharmaceuticals (Canada), Inc., Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2016.03.003_bib1","series-title":"AUA Guideline Diagnosis and Treatment of Interstitial Cystitis\/Bladder Pain Syndrome","author":"Hanno","year":"2014"},{"key":"10.1016\/j.juro.2016.03.003_bib2","series-title":"Campbell-Walsh Urology, 10th ed","article-title":"Bladder pain syndrome (interstitial cystitis) and related disorders","author":"Hanno","year":"2011"},{"key":"10.1016\/j.juro.2016.03.003_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2011.03.132","article-title":"Prevalence of symptoms of bladder pain syndrome\/interstitial cystitis among adult females in the United States","volume":"186","author":"Berry","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.juro.2012.08.088","article-title":"The prevalence and overlap of interstitial cystitis\/bladder pain syndrome and chronic prostatitis\/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study","volume":"189","author":"Suskind","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","article-title":"Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA Guideline amendment","volume":"193","author":"Hanno","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib6","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.juro.2014.11.016","article-title":"Comparison of baseline urological symptoms in men and women in the MAPP research cohort","volume":"193","author":"Clemens","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib7","first-page":"337","article-title":"Diagnosing interstitial cystitis in women with chronic pelvic pain","volume":"100","author":"Clemons","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.juro.2016.03.003_bib8","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.juro.2006.11.084","article-title":"Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women","volume":"177","author":"Clemens","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-5347(05)67376-4","article-title":"Quality of life among women with interstitial cystitis","volume":"164","author":"Michael","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib10","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02000309","article-title":"Interstitial cystitis: an unsolved enigma","volume":"4","author":"Moutzouris","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.juro.2016.03.003_bib11","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1016\/j.juro.2009.02.030","article-title":"The relationship among symptoms, sleep disturbances and quality of life in patients with interstitial cystitis","volume":"181","author":"Nickel","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0022-5347(05)64075-X","article-title":"Coping strategies in patients with interstitial cystitis: relationships with quality of life and depression","volume":"169","author":"Rothrock","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.urology.2011.12.053","article-title":"Suicidal ideation among patients with bladder pain syndrome\/interstitial cystitis","volume":"80","author":"Hepner","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.juro.2016.03.003_bib14","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.juro.2008.06.032","article-title":"Mental health diagnoses in patients with interstitial cystitis\/painful bladder syndrome and chronic prostatitis\/chronic pelvic pain syndrome: a case\/control study","volume":"180","author":"Clemens","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00019053-200624010-00005","article-title":"Interstitial cystitis: cost, treatment and co-morbidities in an employed population","volume":"24","author":"Wu","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.juro.2016.03.003_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.eururo.2011.07.069","article-title":"Contemporary management of the painful bladder: a systematic review","volume":"61","author":"Giannantoni","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib17","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/bph.12039","article-title":"Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in\u00a0vitro and pharmacokinetic characterization in\u00a0vivo","volume":"168","author":"Stenton","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.juro.2016.03.003_bib18","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/cea.12370","article-title":"The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma","volume":"44","author":"Leaker","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.juro.2016.03.003_bib19","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/bph.12038","article-title":"Characterization of AQX-1125, a small-molecule SHIP1 activator: part 2. Efficacy studies in allergic and pulmonary inflammation models in\u00a0vivo","volume":"168","author":"Stenton","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.juro.2016.03.003_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.eururo.2011.10.004","article-title":"The bladder pain\/interstitial cystitis symptom score: development, validation, and identification of a cut score","volume":"61","author":"Humphrey","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0090-4295(99)80333-1","article-title":"The interstitial cystitis symptom index and problem index","volume":"49","author":"O'Leary","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.juro.2016.03.003_bib22","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.juro.2010.12.088","article-title":"Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis","volume":"185","author":"Evans","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2012.05.010","article-title":"Investigation of a Ca2+ channel alpha2delta ligand for the treatment of interstitial cystitis: results of a randomized, double-blind, placebo controlled phase II trial","volume":"188","author":"Nickel","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.03.003_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.juro.2016.03.003_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations","volume":"146","author":"Dworkin","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.juro.2016.03.003_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.urology.2005.07.014","article-title":"Responsiveness of symptom scales for interstitial cystitis","volume":"67","author":"Propert","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.juro.2016.03.003_bib27","series-title":"Incontinence, 5th ed","first-page":"1581","article-title":"Committee 19: bladder pain syndrome","author":"Dinis","year":"2013"}],"updated-by":[{"DOI":"10.1016\/j.juro.2016.10.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000}}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716033681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716033681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2016.03.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T04:44:30Z","timestamp":1651207470000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2016.03.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1016\/j.juro.2016.03.003"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2016.03.003","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis\/Bladder Pain Syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2016.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}